Last checked at 
(Alliance News) - Oxford Nanopore Technologies PLC on Wednesday said it is collaborating with UK Biobank for an "epigenetic dataset targeting the causes of cancer, dementia, complex disease".
UK Biobank is a biomedical database and research resource.
The Oxford-based DNA and RNA sequencing specialist said the partnership will "analyse the epigenome using 50,000 participant samples". Epigenetics is the study of how lifestyle choices can change DNA.
Oxford Nanopore expects no change from the partnership to its 2024 and medium-term financial guidance but noted that incremental revenue will support its previously stated revenue target of over 30% constant currency growth, on a compound annual growth rate between 2024 and 2027.
"This project represents a significant leap forward in epigenetics research, an increasingly important area of study related to causes of disease, disease progression and response to treatment. Working with UK Biobank to create the world's largest epigenetic dataset aligns with our commitment to drive discovery in healthcare and genomics," Chief Executive Officer Gordon Sanghera said. "By capturing comprehensive methylation data, we aim to open new doors for understanding disease, especially cancer and dementia, and ultimately enable more personalised, effective treatments for patients."
According to FTSE Russell on Tuesday, Oxford Nanopore is set for FTSE 250 promotion.
Set to exit the FTSE 250 are clean energy technology developer Ceres Power Holdings PLC; bank, broker and asset manager Close Brothers Group PLC; Carex owner PZ Cussons PLC; and oilfield and engineering services provider John Wood Group PLC.
Food delivery firm Deliveroo PLC, US-focused natural gas producer Diversified Energy Co PLC, transport operator Mobico Group PLC and Oxford Nanopore are set to replace them.
The Oxford-based DNA and RNA sequencing specialist
Oxford Nanopore shares rose 3.2% to 140.41 pence each on Wednesday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to newsroom@alliancenews.com
Copyright 2024 Alliance News Ltd. All Rights Reserved.
